Massia et al.

Response to Restriction/Election Requirement on 11/15/2006

CLAIMS:

- (Original) The composition comprising 2-amino-6-[(2-amino-5{guanidine}pentanoyl) amino] hexanoic acid (AAGPAHA).
- 2. (Original) A method of synthesizing an RGD peptidomimetic, the method comprising
- a. combining equal equivalents of Fmoc-Arg(Pbf)-OH and N-[(dimethylamino)-1H-1,2,3-triazolo[4,5-b]pyridine-1-ylmethylene]-N-methylmethanaminium hexafluorophosphate N-oxide (HATU) and dissolving in 0.5 M diisopropylethylamine in dimethylformamide (DMF);
- b. preparing Boc-Lys (Fmoc)-resin by soaking in 20% piperidine and DMF;
- c. combining the mixture of step a with the Boc-Lys-resin and allowing it to react; and
- d. purifying the reaction mixture of c by washing with DMF and 20% piperidine.
- 3. (Withdrawn) A method of encouraging cell attachment in cell culture, the method comprising
 - a. providing a cell culture substrate; and
- b. adding the compound of claim 1 to the cell culture substrate.
- 4. (Original) An implant resisting cellular interaction after implantation, the implant comprising
 - a. the implant; and

Response to Restriction/Election Requirement on 11/15/2006

- b. a coating on the implant comprising the composition of claim 1.
- 5. (Original) A biomaterial suitable for implantation, the biomaterial capable of resisting cellular interaction after implantation, the biomaterial comprising
 - a. the biomaterial; and
- b. a coating on the biomaterial comprising the composition of claim 1.
- 6. (Original) A pharmaceutical composition comprising
 - a. AAGPAHA; and
 - b. a pharmaceutical excipient.
- 7. (Withdrawn) A method of treating cancer in an individual suffering therefrom, the method comprising
- a. providing the pharmaceutical composition of claim 6; and
- b. administering the pharmaceutical composition to the individual.
- 8. (Withdrawn) A method of treating thrombosis in an individual suffering therefrom, the method comprising
- a. providing the pharmaceutical composition of claim 6; and
- administering the pharmaceutical composition to the individual.
- 9. (Withdrawn) A method of treating osteoporosis in an individual suffering therefrom, the method comprising

USPTO Serial No.: 10/549,518

Massia et al.

Response to Restriction/Election Requirement on 11/15/2006

- a. providing the pharmaceutical composition of claim 6;
 and
- b. administering the pharmaceutical composition to the individual.
- 10. (Withdrawn) A method of treating retinopathy in an individual suffering therefrom, the method comprising
- a. providing the pharmaceutical composition of claim 6;
- b. administering the pharmaceutical composition to the individual.
- 11. (Withdrawn) A method of treating renal insufficiency in an individual suffering therefrom, the method comprising
- a. providing the pharmaceutical composition of claim 6; and
- $\hbox{b.} \quad \text{administering the pharmaceutical composition to the } \\ \hbox{individual.}$
- 12. (Withdrawn) A method of treating wounds in an individual having at least one wound, the method comprising
- a. providing the pharmaceutical composition of claim 6;
- $\hbox{b.} \quad \text{administering the pharmaceutical composition to the } \\ \text{individual.}$
 - a pharmaceutical excipient.